Effecty vs TrueMe
Two GLP-1 desks, one scoreboard. We put Effecty and TrueMe head-to-head on the published Brief Score — the same six factors, scored the same way.
Effecty
The verdict
Effecty takes this head-to-head.
Effecty scores 86 to 72 on our six-factor Brief Score — One of the few accredited desks pairing compounded pricing with brand-name access, nationwide.
That doesn't make TrueMe a bad call — it's best for readers who want flat all-inclusive glp-1 pricing with no membership fee, if you live in one of its six states. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Effecty | TrueMe | |
|---|---|---|
| Brief Score | 86/100 (B) | 72/100 (C) |
| Semaglutide | $160/mo | From $159/mo (compounded) |
| Tirzepatide | $240/mo | From $189/mo (compounded) |
| Coverage | All 50 states | 6 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Effecty: $160 sema / $240 tirz; LegitScript-certified with brand-name access nationwide.
TrueMe: New to the tracker on 1 August 2026. The published line reads From $159/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.